ScreenerHero
FAEFaes Farma, S.A.
BME · ES · Healthcare · Drug Manufacturers - Specialty & Generic · faesfarma.com
4.530EUR-0.44%Mkt Cap: 1.54B $P/E: 16.85

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Anima…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.54B $
Enterprise Value1.88B $
Revenue (TTM)772.89M $
Gross Profit430.34M $
Net Income (TTM)86.55M $
Revenue/Share2.483 USD
Last Price4.530 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.6K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0134950F36
Valuation
P/E (Trailing)16.85
P/E (Forward)12.91
PEG0.91
EV/EBITDA13.76
EV/Revenue2.43
P/S1.99
P/B1.83
EPS (TTM)0.27
EPS (Forward)0.35
52W Range
4.10032% of range5.440
52W High5.440 EUR
52W Low4.100 EUR
Profitability
Gross Margin64.85%
Oper. Margin17.04%
EBITDA Margin17.68%
Profit Margin13.04%
ROE10.69%
ROA5.93%
Growth
Revenue Growth24.00%
Earnings Growth8.90%
Cash Flow & Leverage
Operating CF85.32M $
CapEx (TTM)25.70M $
FCF Margin2.75%
FCF Yield1.38%
Net Debt339.68M $
Net Debt/EBITDA2.49
Balance Sheet
Debt/Equity0.57
Current Ratio2.63
Quick Ratio1.66
Book Value/Sh2.487 EUR
Cash/Share0.4390 EUR
Dividends
Fwd Div Rate0.1300 EUR
Trail. Div Rate0.0870 EUR
Div. Yield2.84%
5Y Avg Yield3.70%
Payout Ratio47.76%
Ex-Div DateJul 2, 2026
Pay Date—
Splits
Last Split27:26
Split DateApr 12, 2023
Analyst Consensus
Rating—
Target (Mean)5.355 EUR
Upside (mean)+18.2%
Target Range4.820 EUR – 6.000 EUR
€4.820+18.2% to mean€6.000
# Analysts4
Ownership
Shares Out.311.45M
Float217.25M
Insiders20.35%
Institutions15.68%
Technical
SMA 504.528 (+0.0%)
SMA 2004.771 (-5.0%)
Beta0.34
S&P 52W Chg18.16%
Avg Vol (30d)79.31K
Avg Vol (10d)79.52K
Technical Indicators
RSI (14)53.7
MACD-0.0018
MACD Signal-0.0030
MACD Hist.+0.0012
BB Upper4.614 EUR
BB Middle4.535 EUR
BB Lower4.456 EUR
BB Width3.49%
ATR (14)0.0751 EUR
Vol Ratio (20d)0.67x